Post-traumatic stress disorder affects an estimated 3.6% of U.S. adults in a given year, and for many people, first-line treatments such as psychotherapy and medication provide meaningful but incomplete relief (National Institute of Mental Health [NIMH], n.d.). If you’ve been through EMDR, prolonged exposure therapy, or multiple medication trials and still find yourself cycling through intrusive memories, hypervigilance, or emotional numbness, you’re not alone, and you’re not out of options. At Mindful Infusions in Salt Lake City, we treat patients across the Wasatch Front who are living with PTSD that has resisted conventional care, and IV ketamine therapy, used off-label for psychiatric conditions, is one of the options we discuss and offer.
Understanding how ketamine intersects with PTSD requires an honest look at both the neuroscience and the clinical evidence. Our goal at Mindful Infusions is never to oversell a treatment or offer false reassurance. We know that patients living with trauma may have already placed trust in treatments that disappointed them. What we can offer is a clear-eyed picture of what the evidence shows, where its limits remain, and what treatment may involve.
PTSD and the Trauma-Conditioned Brain
PTSD has psychological, physiological, and neurobiological dimensions. Neuroimaging research has identified patterns involving the amygdala, hippocampus, and prefrontal regions, which are involved in threat detection, memory, and emotional regulation (Hayes et al., 2012). These patterns do not define any individual person’s experience, but they help explain why symptoms such as nightmares, avoidance, emotional reactivity, emotional numbness, and trauma-induced paralysis can feel so persistent.
Current PTSD guidelines prioritize trauma-focused psychotherapies, including cognitive processing therapy, EMDR, and prolonged exposure therapy (U.S. Department of Veterans Affairs & U.S. Department of Defense [VA/DoD], 2023). At Mindful Infusions, we’ve observed that many patients come to us with long treatment histories, significant symptom burden, and a genuine willingness to engage in recovery. They simply have not found the right combination yet. Our overview of the evolution of PTSD treatment in the last decade explores how care approaches have continued to evolve.
How Ketamine May Help PTSD
Ketamine is an NMDA, or N-methyl-D-aspartate, receptor antagonist. Research on ketamine’s rapid antidepressant effects suggests that NMDA receptor blockade can influence glutamate signaling, synaptic plasticity, and BDNF-related pathways (Abdallah et al., 2015). These mechanisms provide a rationale for continued PTSD research, but they do not establish ketamine as a proven PTSD treatment for every person.
The clinical evidence for ketamine in PTSD is earlier-stage than the evidence base for treatment-resistant depression. A 2014 randomized trial found that a single IV ketamine infusion produced greater PTSD symptom reduction than midazolam at 24 hours in adults with chronic PTSD (Feder et al., 2014). In a later randomized trial of 30 participants, six ketamine infusions over two weeks were associated with greater symptom reduction than midazolam, with 67% of ketamine participants meeting the study’s response criteria at week two (Feder et al., 2021).
These findings are encouraging, but they come from relatively small studies, and questions remain about durability, ideal treatment schedules, and who is most likely to benefit. The VA/DoD guideline suggests against ketamine for the overall treatment of PTSD because the available evidence remains limited. We believe patients deserve to understand both the promising findings and the unanswered questions before deciding whether to move forward. For a broader look at how ketamine has been transforming care for mood disorders, see our post on how ketamine clinics are revolutionizing depression treatment.
Ketamine’s Off-Label Status for PTSD
It is important to be direct: IV ketamine for PTSD is off-label use. Ketamine does not carry FDA approval for PTSD. Neither does SPRAVATO® for this indication. SPRAVATO® is FDA-approved for treatment-resistant depression in adults and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, not for PTSD (U.S. Food and Drug Administration [FDA], 2025).
When we discuss IV ketamine for PTSD at Mindful Infusions, we disclose that distinction clearly from the first consultation. Off-label use does not automatically mean a treatment is inappropriate, but it does mean that FDA approval has not been granted for that indication. Discuss this directly with your provider when considering ketamine for PTSD. You can also review our PTSD treatment in Salt Lake City service page for more information on how we approach care for this condition.
What Integration with PTSD Therapy Looks Like
At Mindful Infusions, we offer ketamine-assisted psychotherapy in Salt Lake City as a separate service, and we encourage patients pursuing ketamine for PTSD to maintain engagement with a trauma-informed therapist whenever possible.
The idea of a neuroplasticity window following ketamine treatment remains an active area of study. Current PTSD guidance finds insufficient evidence to recommend for or against combining psychotherapy and medication strategies for PTSD (VA/DoD, 2023). We do not promise that ketamine will make trauma-focused therapy more effective. Instead, we help you think through how ketamine may fit within your existing care, treatment goals, and support system.
For patients living throughout the Wasatch Front, our Salt Lake City clinic offers a central place to begin that conversation. Our providers take time during your evaluation to understand your treatment history and help you consider how ketamine may fit within your broader care.
What to Expect During Treatment
The IV ketamine infusion experience at Mindful Infusions involves a 45 to 60 minute session in a calm, private setting with continuous monitoring. We prepare you for possible perceptual or dissociative effects, explain what we are monitoring, and make sure you know how to communicate with us if anything feels uncomfortable. Our guide to navigating your first visit to a ketamine clinic can help you prepare before a consultation.
You will need a driver for each session and should plan to rest for the remainder of the day. Our ketamine FAQs address common questions about transportation, timing, monitoring, and candidacy.
Research protocols for PTSD have included a series of six infusions over two weeks, but the number and timing of sessions at Mindful Infusions are individualized based on your evaluation, treatment plan, and response. Additional infusions may be discussed after the initial course for patients who benefit.
Key Takeaways
- IV ketamine for PTSD is off-label use. It is not FDA-approved for PTSD, and we disclose this clearly in every consultation.
- PTSD is associated with changes in brain systems involved in threat detection, memory, and emotional regulation, including the amygdala, hippocampus, and prefrontal regions (Hayes et al., 2012).
- Small randomized trials have found rapid PTSD symptom reduction after IV ketamine for some participants, but long-term outcomes and ideal protocols remain under study (Feder et al., 2014; Feder et al., 2021).
- Trauma-focused therapies such as cognitive processing therapy, EMDR, and prolonged exposure remain strongly recommended in current PTSD guidelines (VA/DoD, 2023).
- We review your treatment history, explain the limits of current evidence, and help you decide whether IV ketamine therapy is a reasonable next step for your situation.
Living with PTSD that has not responded to treatments you’ve already tried is exhausting, and the path forward can feel uncertain. At Mindful Infusions in Salt Lake City, our team takes the time to understand your history, explain your options honestly, and help you decide whether IV ketamine therapy is a reasonable next step. We serve patients across the Wasatch Front and welcome your questions. Call us at (385) 299-0473 or contact us to schedule a consultation.
References
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2015). Ketamine and rapid-acting antidepressants: A window into a new neurobiology for mood disorder therapeutics. Annual Review of Medicine, 66, 509–523. doi: 10.1146/annurev-med-053013-062946
Feder, A., Costi, S., Rutter, S. B., Collins, A. B., Govindarajulu, U., Jha, M. K., Horn, S. R., Kautz, M., Corniquel, M., Collins, K. A., Bevilacqua, L., Glasgow, A. M., Brallier, J., Pietrzak, R. H., Murrough, J. W., & Charney, D. S. (2021). A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. American Journal of Psychiatry, 178(2), 193–202. doi: https://doi.org/10.1176/appi.ajp.2020.20050596
Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., Kirkwood, K., aan het Rot, M., Lapidus, K. A. B., Wan, L. B., Iosifescu, D. V., & Charney, D. S. (2014). Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: A randomized clinical trial. JAMA Psychiatry, 71(6), 681–688. doi: 10.1001/jamapsychiatry.2014.62
Hayes, J. P., Hayes, S. M., & Mikedis, A. M. (2012). Quantitative meta-analysis of neural activity in posttraumatic stress disorder. Biology of Mood & Anxiety Disorders, 2, Article 9. doi: 10.1186/2045-5380-2-9
National Institute of Mental Health. (n.d.). Post-traumatic stress disorder. U.S. Department of Health and Human Services. https://www.nimh.nih.gov/health/statistics/post-traumatic-stress-disorder-ptsd
U.S. Department of Veterans Affairs & U.S. Department of Defense. (2023). VA/DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder: Provider summary. https://www.healthquality.va.gov/guidelines/MH/ptsd/VA-DoD-CPG-PTSD-Provider-Summary.pdf
U.S. Food and Drug Administration. (2025). SPRAVATO® (esketamine) nasal spray prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf
Medical Disclaimer
The information in this blog is for educational purposes only and does not constitute medical advice. Ketamine infusion therapy and SPRAVATO® should only be pursued under the supervision of a licensed provider familiar with your full medical and psychiatric history. Individual results vary. SPRAVATO® is FDA-approved for specific indications; IV ketamine for psychiatric conditions is used off-label. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.